Jazz Pharmaceuticals plc

Total Valuation

Jazz Pharmaceuticals plc carries a market capitalization of 14.19B, placing it among publicly traded companies globally. Its enterprise value stands at 14.11B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Jazz Pharmaceuticals plc currently has 62.70M shares outstanding.

Valuation Ratios

Jazz Pharmaceuticals plc trades at a trailing price-to-earnings ratio of 392.37. The price-to-sales ratio is 2.61, and the price-to-book ratio stands at 12.32.

Enterprise Valuation

On an enterprise value basis, Jazz Pharmaceuticals plc trades at an EV/EBITDA multiple of 8.70 and an EV/FCF ratio of 9.41. The EV/Sales ratio of 3.18 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 15.51 provides insight into valuation relative to core operating earnings.

Financial Position

Jazz Pharmaceuticals plc maintains a current ratio of 2.04, meaning it holds 2.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 119.52, indicating elevated leverage, while an interest coverage ratio of 8.95 demonstrates adequate ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, Jazz Pharmaceuticals plc has paid -248.53M in income taxes, reflecting an effective tax rate of 4.42.

Stock Price Statistics

Jazz Pharmaceuticals plc's stock has gained approximately 104.96737% over the past 52 weeks. The 50-day moving average sits at 209.72, while the 200-day moving average is 168.54.

Income Statement

Over the trailing twelve months, Jazz Pharmaceuticals plc generated 4.44B in revenue and converted that into 29.49M in net income, yielding earnings per share of 0.47. EBITDA reached 1.62B, while operating income came in at 910.11M.

Balance Sheet

Jazz Pharmaceuticals plc holds 2.87B in cash and equivalents against 5.42B in total debt, resulting in a net debt position of 3.51B. Total book value stands at 939.30M, with working capital of 2.34B providing operational flexibility.

Cash Flow

Jazz Pharmaceuticals plc produced 1.33B in operating cash flow over the past twelve months. After subtracting -190.55M in capital expenditures, free cash flow totaled 1.14B - equivalent to 18.68 per share.

Margins

Jazz Pharmaceuticals plc operates with a gross margin of 88.00, reflecting its pricing power and cost economics. The operating margin of 20.50 and net profit margin of 0.66 provide insight into operational efficiency.

Dividends & Yields

Scores

Jazz Pharmaceuticals plc posts an Altman Z-Score of 2.92, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.